Get the Stockscreener App
118.00
0.80%
0.94
Pre-market:
119.99
1.99
+1.69%
Sarepta Therapeutics Inc stock is traded at $118.00, with a volume of 633.67K.
It is up +0.80% in the last 24 hours and down -6.17% over the past month.
See More
Previous Close:
$117.06
Open:
$117.75
24h Volume:
633.67K
Relative Volume:
0.71
Market Cap:
$11.66B
Revenue:
$1.64B
Net Income/Loss:
$121.85M
P/E Ratio:
76.62
EPS:
1.54
Net Cash Flow:
$-480.40M
1W Performance:
-5.44%
1M Performance:
-6.17%
6M Performance:
-19.67%
1Y Performance:
+0.81%
1-Day Range:
$115.61
$118.45
1-Week Range:
$114.42
$127.91
52-Week Range:
$102.16
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
118.00 | 11.66B | 1.64B | 121.85M | -480.40M | 1.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-27-24 | Reiterated | Needham | Buy |
| Nov-25-24 | Initiated | H.C. Wainwright | Sell |
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Insider Monkey
Smith Salley Wealth Management Invests $889,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report Says - MSN
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Holdings Cut by Assenagon Asset Management S.A. - MarketBeat
Undercovered Dozen: Lincoln National, Whitecap Resources, NMI Holdings, Healwell AI + - Seeking Alpha
FY2024 Earnings Forecast for SRPT Issued By HC Wainwright - MarketBeat
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely (NASDAQ:SRPT) - Seeking Alpha
Sarepta Therapeutics (NASDAQ:SRPT) Given "Sell" Rating at HC Wainwright - MarketBeat
HC Wainwright Issues Optimistic Forecast for SRPT Earnings - MarketBeat
Sarepta preliminary Q4 revenue beats, but full year just misses - MSN
What 14 Analyst Ratings Have To Say About Sarepta Therapeutics - Benzinga
J&J files a potential blockbuster; Lykos shakes up its board - BioPharma Dive
HC Wainwright Reaffirms Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeat
Harbor Capital Advisors Inc. Acquires 427 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Sarepta, Biogen drugs with accelerated approval under fire in FDA report - Seeking Alpha
Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report Says | Company Business News - Mint
Sarepta Bullish After Another Big Beat For Elevidys - News & Insights
Sarepta Therapeutics (NASDAQ:SRPT) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
U.S, Europe And GCC Antisense Oligonucleotide (ASO) - openPR
Sarepta Previews Q4 Findings, Touts Elevidys Earnings Beat - BioSpace
Neuromuscular Disease Therapeutics Market to Grow by USD 13.73 Billion from 2025-2029, Driven by Novel Approvals and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
Sarepta exceeds revenue forecasts, maintains 2025 guidance - Investing.com India
Sarepta Therapeutics Tops 2024 Net Product Revenue Guidance - MarketWatch
Sarepta Therapeutics (SRPT) Reports Preliminary Fourth Quarter and Full-Year 2024 Net Product Revenue - StreetInsider.com
Sarepta Therapeutics Smashes Revenue Targets as ELEVIDYS Sales Surge 112% in Q4 2024 - StockTitan
Dyno Therapeutics Announces Exercise of Option by Roche for Next-Generation AAV Vector for Neurological Gene Therapy - Business Wire
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Nordea Investment Management AB - MarketBeat
Zacks Research Issues Pessimistic Forecast for SRPT Earnings - MarketBeat
Sarepta Therapeutics' SWOT analysis: gene therapy leader's stock poised for growth - Investing.com Canada
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development (CORRECTED) - Benzinga
Nippon Shinyaku Hit With Royalty Tab After $115 Million Verdict - Bloomberg Law
SRPT February 28th Options Begin Trading - Nasdaq
SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell? - MSN
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference - Benzinga
Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Brokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Target Price at $178.71 - MarketBeat
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
LABU, NTRA, INCY, SRPT: Large Inflows Detected at ETF - Nasdaq
Sarepta Therapeutics Grants 10,660 RSUs to New Employees in Strategic Talent Acquisition Move - StockTitan
Sarepta Therapeutics, Inc. (SRPT): Is This Gene Therapy Stock a Good Buy Right Now? - Insider Monkey
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
Duchenne Muscular Dystrophy Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Sarepta Therapeutics, Santhera Pharma, ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeuti - Barchart
Exploring High Growth Tech Stocks in the US December 2024 - Simply Wall St
Page 4 | SAREPTA THERAPEUTICS, INC Trade Ideas — BIVA:SRPT - TradingView
SAREPTA THERAPEUTICS, INC Trade Ideas — BIVA:SRPT - TradingView
Principal Financial Group Inc. Sells 95,974 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Is Sarepta Therapeutics, Inc. (SRPT) the Best Performing Biotech Stock in 2024? - Insider Monkey
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):